A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
Conditions: Idiopathic Pulmonary Fibrosis; Systemic Sclerosis With Lung Involvement Interventions: Drug: Vixarelimab; Drug: Placebo Sponsor: Genentech, Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials